Inhaled steroid/tobacco smoke particle interactions: A new light on steroid resistance

Respiratory Research

Volumn 10, Issue , 2009, Pages

  Invernizzi, Giovanni ^a   Ruprecht, Ario ^a   De Marco, Cinzia ^a   Mazza, Roberto ^a   Nicolini, Gabriele ^b   Boffi, Roberto ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; FLUORINATED HYDROCARBON; TOBACCO SMOKE; GLUCOCORTICOID; STEROID;

AMBIENT AIR; ARTICLE; LIGHT SCATTERING; METERED DOSE INHALER; MOLECULAR INTERACTION; PARTICLE SIZE; AEROSOL; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG RESISTANCE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; SMOKE; SMOKING; TOBACCO;

ADMINISTRATION, INHALATION; AEROSOLS; ASTHMA; BECLOMETHASONE; DRUG RESISTANCE; GLUCOCORTICOIDS; HUMANS; PARTICLE SIZE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKE; SMOKING; STEROIDS; TOBACCO;

EID: 70249148042     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-10-48     Document Type: Article

References (42)

1. Whitby KT. The physical characteristics of sulfur aerosol. Atmos Environ 1978, 12:135-59.
2. Hinds WC. Aerosol Technology: Properties, Behavior, and Measurement of Airborn Particles. 1999, New York:Wiley.
3. Nazaroff WW, Cass GR. Mathematical modeling of indoor aerosol dynamics. Environ Sci Technol 1989, 23:157-166.
4. Jung CH, Kim YP, Lee KW. Simulation of the influence of coarse mode particles on the properties of fine mode particles. Aerosol Science 2002, 33:1201-1216.
5. Park SH, Kruis FE, Lee KW, Fissan H. Evolution of Particle Size Distributions due to Turbulent and Brownian coagulation. Aerosol Sci Technolog 2002, 36:419-432.
6. Morawska L, Jarmiska M, Bofinger ND. Size characteristics and ageing of environmental tobacco smoke. Sci Total Environ 1997, 196:43-55.
7. Oberdörster G, Finkelstein JN, Johnston C, Gelein R, Cox C, Baggs R, Elder AC. Acute Pulmonary Effects of Ultrafine Particles in Rats and Mice. 2000, Cambridge (MA): Health Effects Institute.
8. Seipenbusch M, Binder A, Kasper G. Temporal Evolution of Nanoparticle Aerosols in Workplace Exposure. Ann Occup Hyg. 2008, 52(8):707-716. 10.1093/annhyg/men067, 18927101.
9. Klepeis NE, Apte MG, Gundel LA, Sextro RG, Nazaroff WW. Determining size-specific emission factors for environmental tobacco smoke particles. Aerosol Science Technol 2003, 37:780-790.
10. Ning Z, Cheung CS, Fu J, Liu MA, Schell MA. Experimental study of environmental tobacco smoke particles under actual indoor environment. Sci Total Environ 2006, 367:822-830. 10.1016/j.scitotenv.2006.02.017, 16753201.
11. Zhu Y, Hinds WC, Kim S, Sioutas C. Concentration and size distribution of ultrafine particle near a major highway. J Air Waste Manag Assoc 2002, 52:1032-1042.
12. Lighty JS, Veranth JM, Sarofim AF. Combustion aerosols: factors governing their size and composition and implications to human health. J Air Waste Manag Assoc. 2000, 50(9):1565-1618.
13. Repace JL, Lowrey AH. Indoor air pollution, tobacco smoke, and public health. Science. 1980, 208(4443):464-472. 10.1126/science.7367873, 7367873.
14. Nelson PR, Kelly SP, Conrad FW. Studies of environmental tobacco smoke generated by different cigarettes. J Air & Waste Manage Assoc 1998, 48:336-344.
15. Clearing the Smoke Assessing the Science Base for Tobacco Harm Reduction. 2001, New York: National Academy Press. Washington, Clearing the Smoke.
16. US Department of Health and Human Services Smoking and tobacco control. National CancerInstitute (NCI): Health effects of exposure to environmental tobacco smoke. The Report of theCalifornia Environmental Protection Agency. Monograph N°10 1999, National Institutes of Health. Bethesda (MD), US Department of Health and Human Services.
17. World Health Organization International Agency For Research On Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 2002, 83. Tobacco Smoke and Involuntary Smoking. Lyon, World Health Organization.
18. Silverman RA, Boudreaux ED, Woodruff PG, Clark S, Camargo CA. Cigarette Smoking Among Asthmatic Adults Presenting to 64 Emergency Departments. Chest. 2003, 123(5):1472-1479. 10.1378/chest.123.5.1472, 12740263.
19. Molimard M, Le Gros V. Impact of patient-related factors on asthma control. J Asthma. 2008, 45(2):109-113. 10.1080/02770900701815727, 18350401.
20. Eisner MD, Katz PP, Yelin EH, Hammond SK, Blanc PD. Measurement of environmental tobacco smoke exposure among adults with asthma. Environ Health Perspect. 2001, 109(8):809-814. 1240408, 11564616, 10.2307/3454823.
21. Pedersen B, Dahl R, Karlstrom R, Peterson CG, Venge P. Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Am J Respir Crit Care Med 1996, 153(5):1519-1529. 8630596., http://ajrccm.atsjournals.org/cgi/content/abstract/153/5/1519
22. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002, 57(3):226-230. 1746270, 11867826, 10.1136/thorax.57.3.226.
23. Tomlinson JE, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax. 2005, 60(4):282-287. 1747368, 15790982, 10.1136/thx.2004.033688.
24. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, Deykin A, DiMango E, Fish JE, Ford JG, Israel E, Kiley J, Kraft M, Lemanske RF, Leone FT, Martin RJ, Pesola GR, Peters SP, Sorkness CA, Szefler SJ, Wechsler ME, Fahy JV, . National Heart Lung and Blood Institute's Asthma Clinical Research Network Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007, 175:783-90. 1899291, 17204725, 10.1164/rccm.200511-1746OC, National Heart Lung and Blood Institute's Asthma Clinical Research Network.
25. ERS Task Force European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J. 2001, 18(1):228-242. 10.1183/09031936.01.00220001, 11510796, ERS Task Force.
26. Guidance for Industry Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products Chemistry, Manufacturing, and Controls Documentation. 1998, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Guidance for Industry., http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070573.pdf
27. Invernizzi G, Ruprecht A, De Marco C, Paredi P, Boffi R. Residual tobacco smoke: measurement of its washout time in the lung and of its contribution to environmental tobacco smoke. Tob Control. 2007, 16(1):29-33. 10.1136/tc.2006.017020, 17297070.
28. WHO Model List of Essential Medicines. 2007, 15, WHO., http://www.who.int/medicines/publications/08_ENGLISH_indexFINAL_EML15.pdf
29. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998, 12(6):1346-1353. 10.1183/09031936.98.12061346, 9877489.
30. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005, 172(12):1497-504. 10.1164/rccm.200410-1414OC, 16192448.
31. Svartengren M, Anderson M, Bylin G, Philipson K, Camner P. Regional deposition of 3.6-micron particles and lung function in asthmatic subjects. J Appl Physiol. 1991, 71(6):2238-2243.
32. Ritchie D, Amos A, Phillips R, Cunningham-Burley S, Martin C. Action to achieve smoke-free homes- an exploration of experts' views. BMC Public Health. 2009, 9:112. 2679738, 19386111, 10.1186/1471-2458-9-112.
33. Haughney J, Price D, Kaplan A, Chrystyn H, Horne R, May N, Moffat M, Versnel J, Shanahan ER, Hillyer EV, Tunsa A, Bjermer L. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med. 2008, 102(12):1681-1693. 10.1016/j.rmed.2008.08.003, 18815019.
34. British Society Nebulizer Project Group Guidelines. Thorax 1997, 52(Suppl 2):S4-S16. 1765861, 9155847, British Society Nebulizer Project Group.
35. Sestini P, Cappiello V, Aliani M, Martucci P, Sena A, Vaghi A, Canessa PA, Neri M, Melani AS. Prescription Bias and Factors Associated with Improper Use of Inhalers. J Aerosol Med. 2006, 19(2):127-136. 10.1089/jam.2006.19.127, 16796537.
36. National Heart, Lung, and Blood Institute National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007, National Heart, Lung, and Blood Institute., http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf
37. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) 2008, http://www.ginasthma.org/Guidelineitem.asp??l1=2&l2=1&intId=60
38. Diette GB, McCormack MC, Hansel NN, Breysse PN, Matsui EC. Environmental Issues in Managing Asthma. Respir Care. 2008, 53(5):602-615. 2396450, 18426614.
39. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, . on behalf of the ISOLDE Study Group Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003, 58:654-658. 1746769, 12885977, 10.1136/thorax.58.8.654, on behalf of the ISOLDE Study Group.
40. GOLD Global Strategy for Diagnosis, management, and Prevention of COPD. 2008, GOLD., http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=2003
41. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med. 2003, 168(11):1308-1311. 10.1164/rccm.200304-503OC, 12893649.
42. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005, 352(19):1967-1976. 10.1056/NEJMoa041892, 15888697.